Project Grant R21CA316106
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $401K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $646,881 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. The research focuses on developing first-in-class small molecule inhibitors targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase protein implicated in acute leukemia pathogenesis. The project addresses the urgent...
- Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $646,920 under the Cancer Treatment Research program (CFDA 93.395) on March 11, 2026, to support research into novel multi-targeted therapeutic strategies for T-cell lymphomas (TCL) and their tumor microenvironment. The five-year project, concluding February 28, 2031, will develop and investigate innovative treatment approaches targeting the interconnected mechanisms that promote...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $640,135 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025 through July 31, 2030. This award supports the development of next-generation menin inhibitors designed to overcome clinical resistance observed in acute myeloid leukemia (AML) patients undergoing menin inhibitor therapy. The research addresses the critical clinical problem of...
- Federal Project Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan $646,671 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research through April 30, 2031. The project focuses on advancing antibody-drug conjugate (ADC) development by identifying optimal payload selections that maximize multiple mechanisms of action for high avidity low affinity (HALA) antibodies. Researchers will delineate the immunological...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $669,278 to the University of Michigan's Office of Research and Sponsored Projects, effective June 1, 2026 through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This Multi-Principal Investigator (MPI) R01 application, aligned with PAR-25-107 (Advancing Microbial-Based Cancer Therapy), supports the development of engineered nonpathogenic tumor-tropic E. coli bacteria...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $571,735 Project Grant (CFDA 93.396, Cancer Biology Research) to the Regents of the University of Michigan, Office of Research and Sponsored Projects, effective July 1, 2026, through June 30, 2031. This research project investigates mechanisms by which disruption of collagen in the extracellular matrix (ECM) potentiates anti-glioma immune responses. Glioblastomas represent the most aggressive primary brain tumors with poor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Michigan $660,808 under the Cancer Biology Research program (CFDA 93.396) on April 7, 2026, to investigate the durability and functionality of tissue-resident memory T cells (TRM) in melanoma treatment response and recurrence prevention. The research will examine how TRM cells with high interferon-gamma expression (TRM-IFNG) established at primary melanoma diagnosis are recalled and expanded to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Michigan a Project Grant totaling $512,292 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to interrogate protein phosphatase 2A (PP2A) as a molecular driver of high-grade endometrial carcinoma and develop targeted therapeutics. The research addresses the critical clinical need to improve survival outcomes for aggressive endometrial cancer subtypes, which have become the deadliest...
- Federal Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $544,868 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026, through May 31, 2031. The award supports research investigating SLC13A3 and its role in tumor resistance to immunotherapy, with a focus on understanding how the itaconate-SLC13A3 metabolic axis suppresses major histocompatibility...
- Federal Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $610,498 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on August 1, 2025, with a completion date of July 31, 2030. This award funds a comprehensive training initiative designed to build nationwide investigator capacity in adaptive intervention methodology for cancer control. The project will deliver didactic...